CSIMarket
 


Respirerx Pharmaceuticals Inc   (RSPI)
Other Ticker:  
 

Respirerx Pharmaceuticals Inc 's Working Capital Ratio

RSPI's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Working Capital Ratio deteriorated to 0.01 below Respirerx Pharmaceuticals Inc 's average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 545 other companies have achieved higher Working Capital Ratio than Respirerx Pharmaceuticals Inc in second quarter 2023. While Working Capital Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 4898 to 5160.

Explain Working Capital Ratio
How much in Current Assets RSPI´s has?
What is the value of RSPI´s Current Liabilities?


RSPI Working Capital Ratio (Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Change 11.25 % 14.76 % 18.21 % 22.68 % 22.5 %
Y / Y Current Assets Change 81.8 % -7.2 % -89.09 % -78 % -45.45 %
Working Capital Ratio MRQ 0.01 0.01 0 0 0.01
RSPI's Total Ranking # 5160 # 4898 # 5214 # 5256 # 5272
Seq. Current Liabilities Change -0.63 % 4.76 % 2.55 % 4.21 % 2.5 %
Seq. Current Assets Change 47.34 % 320.91 % -54.98 % -34.88 % -24.8 %



Working Capital Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 546
Healthcare Sector # 1124
Overall Market # 5160


Working Capital Ratio Statistics
High Average Low
0.13 0.02 0
(Jun 30 2016)   (Dec 31 2022)




Financial Statements
Respirerx Pharmaceuticals Inc 's Current Liabilities $ 12 Millions Visit RSPI's Balance sheet
Respirerx Pharmaceuticals Inc 's Current Assets $ 0 Millions Visit RSPI's Balance sheet
Source of RSPI's Sales Visit RSPI's Sales by Geography


Cumulative Respirerx Pharmaceuticals Inc 's Working Capital Ratio

RSPI's Working Capital Ratio for the trailling 12 Months

RSPI Working Capital Ratio

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth 11.25 % 14.76 % 18.21 % 22.68 % 22.5 %
Y / Y Current Assets TTM Growth 81.8 % -7.2 % -89.09 % -78 % -45.45 %
Working Capital Ratio TTM 0.01 0.01 0.01 0.01 0.02
Total Ranking TTM # 4260 # 4450 # 5071 # 4859 # 5816
Seq. Current Liabilities TTM Growth -0.63 % 4.76 % 2.55 % 4.21 % 2.5 %
Seq. Current Assets TTM Growth 47.34 % 320.91 % -54.98 % -34.88 % -24.8 %


On the trailing twelve months basis In Spite of the decrease in Current Liabilities in the II Quarter 2023 to $12.21 millions, cumulative Working Capital Ratio remained unchanged at 0.01 below the Respirerx Pharmaceuticals Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 527 other companies have achieved higher Working Capital Ratio than Respirerx Pharmaceuticals Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 4242 to 4267.

Explain Working Capital Ratio
How much in Current Assets RSPI´s has?
What is the value of RSPI´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 528
Healthcare Sector # 1094
Within the Market # 5160


trailing twelve months Working Capital Ratio Statistics
High Average Low
0.04 0.02 0.01
(Jun 30 2017)   (Mar 31 2023)




Companies with similar Working Capital Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioJun 30 2023 MRQ Current AssetsJun 30 2023 MRQ Current Liabilities
Bioadaptives Inc   0.03 $ 0.047  Millions$ 1.666  Millions
Novaccess Global Inc   0.03 $ 0.177  Millions$ 6.410  Millions
Hst Global Inc   0.03 $ 0.002  Millions$ 0.089  Millions
Actavia Life Sciences Inc   0.02 $ 0.037  Millions$ 1.697  Millions
Skinvisible Inc   0.02 $ 0.060  Millions$ 2.980  Millions
Bioxytran Inc   0.02 $ 0.045  Millions$ 2.764  Millions
Oncotelic Therapeutics Inc   0.02 $ 0.282  Millions$ 18.086  Millions
Kaya Holdings Inc  0.01 $ 0.150  Millions$ 10.014  Millions
Axim Biotechnologies Inc   0.01 $ 0.107  Millions$ 8.366  Millions
Regen Biopharma Inc  0.01 $ 0.063  Millions$ 5.314  Millions
Respirerx Pharmaceuticals Inc   0.01 $ 0.141  Millions$ 12.210  Millions
Propanc Biopharma Inc   0.01 $ 0.019  Millions$ 3.158  Millions
Biostax Corp  0.01 $ 0.023  Millions$ 3.861  Millions
Theralink Technologies Inc   0.01 $ 0.245  Millions$ 48.081  Millions
Adhera Therapeutics Inc 0.00 $ 0.082  Millions$ 22.869  Millions

Date modified: 2023-08-25T21:47:42+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com